For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The Contract Manufacturing Organization (CMO) is a company that offers a wide range of services, from drug development to pharmaceutical manufacturing, from contracts to pharmaceutical companies. Biopharmaceutical contract manufacturing involves the development and manufacture of biopharmaceutical molecules for biopharmaceutical companies. Biopharmaceuticals include pharmaceutical products such as proteins, nucleic acids, blood components, and vaccines developed from biological sources.
The Biopharmaceutical Contract Manufacturings market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Biopharmaceutical Contract Manufacturings industry, and breaks down according to the type, application, and consumption area of Biopharmaceutical Contract Manufacturings. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Biopharmaceutical Contract Manufacturings in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Biopharmaceutical Contract Manufacturings market covered in Chapter 11:
Recipharm AB
Baxter Biopharma Solutions
Jubilant Life Sciences Ltd.
Cambrex Corporation
Famar
Patheon Inc.
Abbvie Inc.
Catalent Inc.
Lonza
Pfizer Centresource
Boehringer Ingelheim
Aenova
In Chapter 3, on the basis of types, the Biopharmaceutical Contract Manufacturings market from 2018 to 2028 is primarily split into:
Active Pharmaceutical Ingredient (API) Manufacturing
Finished Dosage Formulation (FDF) Development & Manufacturing
Others
In Chapter 4, on the basis of applications, the Biopharmaceutical Contract Manufacturings market from 2018 to 2028 covers:
Oncology
Central Nervous System
Cardiovascular Disorders
Infectious Diseases
Pulmonary Disorders
Metabolic Disorders
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2028) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028